Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD). The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV being developed for the prevention of IPD in adults and children. VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI to prevent dysentery and shigellosis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Vaxcyte Inc.

In a report released yesterday, from Guggenheim reiterated a Buy rating on Vaxcyte, with a price target of $116.00. The company’s shares closed yes...

Vaxcyte (PCVX) Gets a Buy from Guggenheim

Mizuho Securities analyst Salim Syed maintained a Buy rating on Vaxcyte today and set a price target of $163.00. Syed covers the Healthcare sector,...

Market Cap	$5.48B	P/E Ratio	N/A
52W High	$93.77	52W Low	$27.66
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	25.5%
Overall Score	49	Value Score	60
Quality Score	47	Technical Score	41

EPS Current Est	$-5.64	EPS Next Est	$-6.26
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PCVX	$44.50	-0.20%	1.66M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PCVX	$44.50	-0.2%	1.66M
3
4
5
6

PCVX

PCVX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Vaxcyte Inc. Data in Excel

Get Vaxcyte Inc. Data in Excel